XBiotech Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 9, 2019 and accepted by EDGAR at Aug 9, 2019, 15:01 ET.
Management's discussion and analysis
As filed, 18,941 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.
We have never been profitable and, as of June 30, 2019, we had an accumulated deficit of $249.4 million. We had net losses of $5.9 million and $11.7 million for the three months and six months ended June 30, 2019, respectively, compared to $5.9 million and $10.0 million for the three months and six months ended June 30, 2018, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of June 30, 2019, we had 59 employees.
Recent Events:
The Company has recently launched initatives to begin two randomized, double blind, placebo-controlled, multi-center phase 2 studies evaluating bermekimab subcutaneous formulation in adults with moderate to severe Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). Dr. Alice Gottlieb will Chair the HS study, while Dr. Seth Forman will Chair the AD study. This follows the completion of two open label, multi center phase 2 dermatology studies evaluating bermekimab as a treatment for HS and AD. The Company announced positive findings from these studies, both of which were presented at the American Academy of Dermatology’s Annual Meeting in March 2019. The Company plans to enroll the first patients in each study by end of 2019. The Company also announced enrollment completion and positive interim findings for an investigator sponsored study evaluating bermekimab in patients with advanced pancreatic adenocarcinoma and cachexia. The study is being conducted and led by principal investigator Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai Medical Center. Data analysis for this study and future development plans in this indication are on-going. Funding has been awarded by the Medical Research Council (MRC) which promotes research and innovation in the UK, to evaluate bermekimab therapy in a phase 2, multi-center study in advanced lung, pancreatic and ovarian cancers. The phase 2 study will be conducted at multiple cancer centers across the UK. Patients will receive eight weekly doses of bermekimab and be assessed for tumor-related wasting and other quality of life symptoms (using the EORTC QLQ-C30). The study will be led by Dr. Barry Laird, M.D., of the University of Edinburgh. In June the Company closed a public offering of its common shares and successfully raised gross proceeds of approximately $40 million for future development. Piper Jaffray acted as sole underwriter in the offering. In July the Company announced that it added renowned cardiologist and researcher, Dr. Peter Libby, to its Corporate Board of Directors.
XBiotech plans to continue the development of its clinical pipeline along with research and development efforts to enable selection of drug candidates and research projects for further development in response to their preclinical and clinical success and commercial potential.
Risks
The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $44.9 million at June 30, 2019 will enable the Company to achieve some key inflection points, including clinical studies in certain indication(s), as well as on-going R&D efforts for the Company’s pre-clinical pipeline. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of June 30, 2019 will enable us to fund our operating expenses and capital expenditure requirements through June 30, 2020. We have based this estimate on assumptions that may prove to be inaccurate, and we could utilize our available capital resources sooner than we currently expect.
Revenues
To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, bermekimab, or any other product candidate we may advance in the future.
Research and Development Expenses
Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, share-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.
Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through June 30, 2019, we have recorded total research and development expenses, including share-based compensation, of $194.9 million. Our total research and development expenses for the three months and six months ended June 30, 2019 were $4.7 million and $9.2 million, respectively, compared to $3.9 million and $6.9 million for the three months and six months ended June 30, 2018, respectively. Share-based compensation accounted for $0.3 million and $0.6 million for the three months and six months ended June 30, 2019, respectively, compared to $0.2 million and $0.3 million for the three months and six months ended June 30, 2018, respectively.
Research and development expenses, as a percentage of total operating expenses for the three months and six months ended June 30, 2019 were both 78%, compared to 70% and 71% for the three months and six months ended June 30, 2018, respectively. The percentages, excluding share-based compensation, for the three months and six months ended June 30, 2019 were both 80%, compared to 76% and 74% for the three months and six months ended June 30, 2018, respectively.
The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.
Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.
General and Administrative Expenses
General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months and six months ended June 30, 2019 were $1.3 million and $2.6 million, respectively, compared to $1.7 million and $2.8 million for the three months and six months ended June 30, 2018, respectively. Share-based compensation accounted for $0.2 million and $0.5 million for the three months and six months ended June 30, 2019, respectively, compared to $0.5 million and $0.5 million for the three months and six months ended June 30, 2018, respectively.
General and administrative expenses, as a percentage of total operating expenses for the three months and six months ended June 30, 2019 were both 22%, compared to 30% and 29% for the three months and six months ended June 30, 2018, respectively. The percentages, excluding share-based compensation, for the three months and six months ended June 30, 2019 were both 20%, compared to 24% and 26% for the three months and six months ended June 30, 2018, respectively.
Critical Accounting Policies
The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.
Results of Operations
Revenue
We did not record any revenue during the three months and six months ended June 30, 2019 and 2018.
Expenses
Research and Development
Research and Development costs are summarized as follows (in thousands):
| Three Months Ended June 30, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $1,183 | $1,020 | $163 | 16% |
| Laboratory and manufacturing supplies | 1,344 | 424 | 920 | 217% |
| Clinical trials and sponsored research | 241 | 586 | (345) | -59% |
| Share-based compensation | 291 | 162 | 129 | 80% |
| Other | 1,634 | 1,757 | (123) | -7% |
| Total | $4,693 | $3,949 | $744 | 19% |
| Six Months Ended June 30, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $2,349 | $2,072 | $277 | 13% |
| Laboratory and manufacturing supplies | 2,586 | 637 | 1,949 | 306% |
| Clinical trials and sponsored research | 496 | 594 | (98) | -16% |
| Share-based compensation | 586 | 250 | 336 | 134% |
| Other | 3,203 | 3,388 | (185) | -5% |
| Total | $9,220 | $6,941 | $2,279 | 33% |
We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.
Research and development expenses increased 19% to $4.7 million for the three months ended June 30, 2019 compared to $3.9 million for the three months ended June 30, 2018. Research and development expenses increased 33% to $9.2 million for the six months ended June 30, 2019 compared to $6.9 million for the six months ended June 30, 2018.
The three month increase in research and development expenses was mainly due to a $0.9 million increase of laboratory and manufacturing supplies, related to the clinical drug manufacturing for the clinical trial expected to be opened in the remainder of the year. Clinical trials and sponsored research expense decreased due to the completion of two clinical trials started in 2018. In addition, there was an increase in salary and related expenses and share-based compensation due to the increase of our research and development workforce from 40 to 55.
Compared to the six months ended June 30, 2018, the research and development expense increase in the six months ended June 30, 2019 was primarily caused by the increase of laboratory and manufacturing supplies for the clinical trial expected to be opened in the remainder of the year. Labor costs and share-based compensation also increased due to the growing size of the research and development workforce.
General and Administrative
General and administrative costs are summarized as follows (in thousands):
| Three Months Ended June 30, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $211 | $384 | $(173) | -45% |
| Patent filing expense | 170 | 220 | (50) | -23% |
| Share-based compensation | 195 | 475 | (280) | -59% |
| Professional fees | 356 | 136 | 220 | 162% |
| Other | 381 | 457 | (76) | -17% |
| Total | $1,313 | $1,672 | $(359) | -21% |
| Six Months Ended June 30, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $466 | $707 | $(241) | -34% |
| Patent filing expense | 369 | 401 | (32) | -8% |
| Share-based compensation | 470 | 497 | (27) | -5% |
| Professional fees | 540 | 343 | 197 | 57% |
| Other | 746 | 881 | (135) | -15% |
| Total | $2,591 | $2,829 | $(238) | -8% |
General and administrative expenses decreased by 21% to $1.3 million for the three months ended June 30, 2019 compared to $1.7 million for the three months ended June 30, 2018. General and administrative expenses decreased by 8% to $2.6 million for the six months ended June 30, 2019 compared to $2.8 million for the six months ended June 30, 2018.
The three months decrease was primarily related to a $0.3 million decrease in share-based compensation due to the stock options granted to certain consultants in Q2 2018. Salaries and related expense decreased due to the $193 thousand bonus paid to the Chief Executive Officer in June 2018 .
Compared to the six months ended June 30, 2018, , the general and administrative expense decrease in the six months ended June 30, 2018 was primarily caused by the decrease of.salaries and related expense due to the $193 thousand bonus paid to the Chief Executive Officer in June 2018 .
Other income (loss)
The following table summarizes other income (loss) (in thousands):
| Three Months Ended June 30, 2019 | 2018 | Six Months Ended June 30, 2019 | 2018 | |
|---|---|---|---|---|
| Interest income | 51 | 107 | 129 | 170 |
| Other income | 1 | - | 10 | - |
| Foreign exchange gain (loss) | 102 | (393) | (44) | (376) |
| Total | $154 | $(286) | $95 | $(206) |
The interest income for the three months and six months ended June 30, 2019 and 2018 was mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange gain and loss was mainly due to the fluctuation between US dollar and Euro in the three months and six months ended June 30, 2019 compared to the three months and six months ended June 30, 2018.
Liquidity and Capital Resources
Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.
Since our inception on March 22, 2005 through June 30, 2019, we have funded our operations principally through public offerings and the private placement of equity securities, which have provided aggregate cash proceeds of approximately $296.0 million. The following table summarizes our sources and uses of cash (in thousands):
| Net cash (used in) provided by: | Six Months Ended June 30, 2019 | 2018 |
|---|---|---|
| Operating activities | $(9,540) | $(7,426) |
| Investing activities | (37) | (82) |
| Financing activities | 38,636 | 201 |
| Effect of foreign exchange rate on cash and cash equivalents | 39 | 388 |
| Net change in cash and cash equivalents | $29,098 | $(6,919) |
During the six months ended June 30, 2019 and 2018, our operating activities used net cash of $9.5 million and $7.4 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the six months ended June 30, 2019 as compared to the six months ended June 30, 2018 was mainly due to the increase in laboratory and manufacturing supplies.
During the six months ended June 30, 2019 and 2018, our investing activities used net cash of $37 thousand and $82 thousand, respectively. The use of cash was for the purchase of new research and development equipment.
During the six months ended June 30, 2019 and 2018, our financing activities provided net cash proceeds of $38.6 million and $0.2 million, respectively. During the six months ended June 30, 2019, the Company sold 4.8 million shares under the Common Shares Purchase Agreement with Piper Jaffray & Co for net proceeds of approximately $37.5 million. Employees exercised stock options to purchase a total of 255 thousand shares of our common stock for approximately $0.9 million in net proceeds. In this period, the Company also collected $0.3 million of its subscription receivable balance. During the six months ended June 30, 2018, employees exercised stock options to purchase a total of 81 thousand shares of our common stock for approximately $0.2 million in net proceeds.
We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized. As of June 30, 2019, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $44.9 million.
Off-Balance Sheet Arrangements
Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.
Market risk
As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.
Controls and procedures
As filed, 1,805 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management's Evaluation of our Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the second quarter of the year ended December 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-04-01 to 2019-06-30 | $4.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$6.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$11.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$5.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$11.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$9.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $37.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $44.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $45.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $71.9m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $2.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $2.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $69.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-19-005378. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.